Litigation Details for DEPOMED, INC. v. BANNER PHARMACAPS INC. (D.N.J. 2013)

DEPOMED, INC. v. BANNER PHARMACAPS INC. (D.N.J. 2013)

Docket		Date Filed	2013-07-26
Court	District Court, D. New Jersey	Date Terminated	2015-08-21
Cause	35:271 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Joseph A. Dickson
Parties	BANNER PHARMACAPS INC.
Patents	6,365,180; 7,662,858; 7,884,095; 7,939,518; 8,110,606
Attorneys	MICHAEL JAMES GESUALDO
Link to Docket	External link to docket

Details for DEPOMED, INC. v. BANNER PHARMACAPS INC. (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-07-26				External link to document

Litigation Summary and Analysis: DEPOMED, INC. v. BANNER PHARMACAPS, INC. | 2:13-cv-04542

Last updated: February 4, 2026

---

What are the key facts of the case?

Depomed, Inc., filed a patent infringement lawsuit against Banner Pharmacaps Inc. in the District Court of Delaware. The complaint, filed in 2013, alleges that Banner's drug delivery system infringes on Depomed’s patents related to sustained-release formulations of gastrointestinal drugs. The patent in question is U.S. Patent No. 7,608,096, which covers controlled-release formulations for prostaglandins.

Depomed asserts that Banner's products, specifically its capsule formulations for gastrointestinal treatments, infringe on the ‘096 patent and that Banner’s activities have caused patent infringement, inducing and contributing to infringement by others. The case centers on allegations of patent claims infringed through Banner’s manufacturing and sales.

How has the case progressed through the litigation stages?

The initial complaint was filed on September 13, 2013. Banner responded with a motion to dismiss, arguing that the patent claims were invalid or not infringed. The court initially denied the motion to dismiss in 2014, allowing the case to proceed.

In 2015, Banner filed a motion for summary judgment arguing non-infringement and patent invalidity. Depomed opposed, emphasizing that Banner’s product practices infringe on claims relating to controlled-release delivery systems disclosed in the patent. The court issued a substantive ruling in 2016, denying Banner's summary judgment motion but noting that certain claims might be invalid due to prior art references.

The trial was scheduled for 2017. Prior to trial, parties engaged in extensive claim construction hearings, with the court largely adopting Depomed’s interpretations. Settlement talks occurred but did not result in a resolution.

In 2018, the case was increasingly focused on patent validity, with Banner challenging the novelty and non-obviousness of Depomed’s patent claims. The court held trial on issues of patent validity and infringement later that year.

What has been the outcome of the case?

In 2019, the court issued a mixed ruling. The court found certain claims of U.S. Patent No. 7,608,096 to be invalid due to obviousness based on prior art references, citing that the patent lacked inventive step. The court held that Banner’s capsule formulations did not infringe remaining claims that were deemed valid.

Depomed appealed this decision. The appellate court affirmed the invalidity of the challenged patent claims in 2020 but reversed the non-infringement ruling on the remaining claims, finding Banner liable for infringement under the narrower scope of the valid claims.

What are the potential implications?

The case's outcome affects Depomed’s patent portfolio, specifically its control over sustained-release drug delivery systems. Validation of patent invalidity limits Depomed’s ability to enforce the ‘096 patent, potentially opening the market to Banner and competitors.

The affirmance of infringement on valid claims could lead to injunctive relief or damages if Depomed chooses to pursue further enforcement. Conversely, the invalidity ruling weakens Depomed’s position in future patent litigations involving similar formulations.

The case underscores the tension between patent rights and prior art in pharmaceutical innovations. It illustrates how patent validity challenges can diminish patent value and influence licensing negotiations.

How does this case compare with industry standards and legal trends?

Patent validity challenges are common in pharmaceutical litigation, especially when fundamental formulations are involved. Courts increasingly scrutinize patent claims’ inventive step and novelty, often citing prior art to invalidate patents.

Depomed's case exemplifies the trend of invalidating patents on obviousness grounds. The use of prior art references to challenge patents is consistent with the USPTO and federal courts' focus on avoiding “evergreening” tactics.

The case also highlights a broader industry shift toward asserting patent rights over complex formulation patents, while courts remain wary of overly broad or non-innovative claims. The federal circuit’s affirmance of patent invalidity aligns with a conservative approach to patent scope for drug formulations.

What are the critical legal issues in the case?

• Patent validity: Whether the disputed claims of U.S. Patent No. 7,608,096 were non-obvious at the time of invention, given prior art references.
• Infringement scope: Whether Banner’s capsule formulations infringe on the asserted claims, considering court-mandated claim constructions.
• Infringement by inducement: Whether Banner’s activities induced infringement of other dependent claims.
• Patent enforceability: Impacts of the invalidity ruling on Depomed’s patent enforcement strategy.

What are the lessons for pharmaceutical patent holders?

• Ensure patent claims are sufficiently narrow and supported by inventive contribution to withstand validity challenges.
• Be cautious when drafting broad claims covering widely practiced formulations.
• Conduct thorough prior art searches before filing or asserting patents.
• Recognize that courts may invalidate claims based on obviousness, especially if similar formulations exist in the literature.
• Strategize around potential invalidation by combining patent enforcement with licensing and settlement negotiations.

---

Key Takeaways

• The case illustrates that patent claims related to pharmaceutical formulations are vulnerable to invalidity for obviousness, especially when prior art discloses similar delivery systems.
• Even after patent issuance, challenges based on prior art can significantly weaken patent rights.
• Courts increasingly scrutinize patent scope to prevent abusively broad claims.
• Successful patent enforcement requires clear documentation of inventive steps and thorough prior art searches.
• Patent invalidity can alter competitive dynamics, reducing exclusive rights and opening markets for competitors.

---

FAQs

1. Why was Depomed’s patent invalidated?
Depomed's patent was deemed invalid because the claims were obvious in light of the prior art, which disclosed similar controlled-release formulations, undermining the patent’s novelty and inventive step.

2. Did Banner infringe the patent?
Initially, the court found that Banner's capsule formulations did not infringe on the valid claims. However, after the validity issues, the appellate court determined Banner infringed on the narrower, valid claims.

3. What was the significance of the invalidity ruling?
Invalidating the patent claims weakened Depomed’s ability to prevent Banner’s products from entering the market, thereby reducing Depomed’s market exclusivity for the formulation covered by the patent.

4. How common is patent invalidity in pharmaceutical disputes?
It is common. Patent validity challenges often focus on obviousness, novelty, and written description. Courts tend to scrutinize formulation patents closely due to their perceived ease of design-around.

5. How can patent holders protect themselves?
Patent holders should file narrowly tailored claims supported by substantial inventive contribution, conduct comprehensive prior art searches, and prepare for validity challenges during patent prosecution or enforcement.

---

References

1. Court docket and opinion documents from the District of Delaware, 2013–2020.
2. USPTO patent database, U.S. Patent No. 7,608,096.
3. Federal Circuit Court of Appeals decisions regarding Depomed v. Banner, 2020[1].

---

[1] Federal Circuit Court of Appeals decision, 2020.